How do typical and atypical antipsychotics differ in their dopaminergic mechanisms for addressing positive symptoms?

How do typical and atypical antipsychotics differ in their dopaminergic mechanisms for addressing positive symptoms?

• A. Atypical antipsychotics do not interact with serotonin receptors.
• B. Typical and atypical antipsychotics have identical receptor profiles.
• C. Typical antipsychotics stimulate dopamine receptors.
• D. Typical antipsychotics primarily block D2 receptors in mesolimbic pathways; atypical antipsychotics also block D2 with 5-HT2A antagonism to improve efficacy and reduce extrapyramidal side effects.

Answer: (D)

The key idea is that controlling positive symptoms relies on reducing dopamine signaling in the mesolimbic pathway. Typical antipsychotics do this mainly by strongly blocking D2 receptors in that pathway, which lowers positive symptoms but often causes extrapyramidal side effects because dopamine in other pathways (like the nigrostriatal tract) also gets blocked. Atypical antipsychotics still block D2 receptors, but they also antagonize serotonin 5-HT2A receptors. This 5-HT2A antagonism modulates dopamine release in other circuits, which helps lessen motor side effects while maintaining or improving efficacy against positive symptoms. So the combination of D2 blockade with 5-HT2A antagonism explains why atypicals can address positive symptoms effectively with better tolerability.

The key idea is that controlling positive symptoms relies on reducing dopamine signaling in the mesolimbic pathway. Typical antipsychotics do this mainly by strongly blocking D2 receptors in that pathway, which lowers positive symptoms but often causes extrapyramidal side effects because dopamine in other pathways (like the nigrostriatal tract) also gets blocked. Atypical antipsychotics still block D2 receptors, but they also antagonize serotonin 5-HT2A receptors. This 5-HT2A antagonism modulates dopamine release in other circuits, which helps lessen motor side effects while maintaining or improving efficacy against positive symptoms. So the combination of D2 blockade with 5-HT2A antagonism explains why atypicals can address positive symptoms effectively with better tolerability.